Overview
T-MAXIMUM PHARMACEUTICAL, a biotechnology company specialising in universal cell-based therapies, has received international praise for its pioneering work in allogeneic CAR-T cell therapy.
About MT027
- MT027, the lead product in T-MAXIMUM’s pipeline, is an allogeneic CAR-T therapy modified using CRISPR/Cas9 technology to target the B7-H3 tumour antigen in recurrent glioblastoma and other solid tumours.
- Early studies have shown it to be both effective and safe.
- MT027 could potentially treat various late-stage solid tumours, offering hope to patients with aggressive cancers.
Preparation for Registrering MT027
- T-MAXIMUM is preparing MT027 for registration and clinical trials in the United States, with manufacturing already finalised and partnerships established with third-party manufacturers in China and the United States.
- The product has received Orphan Drug Designation from the US FDA, which could expedite its approval process.
- In addition to MT027, the company is developing two other allogeneic CAR-T therapies: MT026, targeting IL13Rα2 for solid tumours, and MT020, aimed at treating B-cell related autoimmune diseases.
For Novel Allogeneic CAR-T Therapies
- T-MAXIMUM, has also announced the development of next-generation allogeneic CAR-T therapies for solid tumours, which will involve more advanced T-cell engineering.
- The company is exploring strategies to combine CAR-T cells with other treatments to improve disease control in advanced solid tumours, ultimately aiming to transform these tumours into manageable chronic conditions.
About Traditional CAR-T Cell Therapies
- Traditional CAR-T cell therapies typically use a patient’s own cells, which can be time-consuming and expensive to produce.
- This method also carries risks, including the potential for manufacturing failures and insufficient T cells in patients who have undergone extensive treatments.
- In contrast, allogeneic CAR-T therapies use T cells from healthy donors, which are more abundant and functional.
- This approach allows for the creation of ""off-the-shelf"" products, offering a more scalable and accessible treatment option.
About Solid Tumours
- Solid tumours, which make up about 90% of all cancers, represent a significant unmet medical need, especially in their late stages.
- While cell therapies have shown success in treating blood cancers, progress in solid tumours has been limited.
- T-MAXIMUM’s allogeneic CAR-T therapies are designed to enhance effectiveness and overcome rejection issues, making them a promising tool against solid tumours like glioblastoma.
- Initial clinical trials have shown encouraging results, with the therapy demonstrating a favourable safety profile in over 50 patients.
Trial Presentation at ASCO
- The company recently presented a trial at the 2024 American Society of Clinical Oncology (ASCO) Breakthrough Summit, focusing on the use of B7H3-specific allogeneic CAR-T cells for treating recurrent high-grade glioma.
- This study, involving intrathecal or intracerebroventricular administration, was awarded one of only 40 Abstract Awards at the conference.
